Latest news with #CriticalInfrastructureManufacturingFeasibilityAct
Associated Press
29-05-2025
- Business
- Associated Press
GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing
Highlights Broad National Support for Domestic Vaccine Resilience and Role of MVA Platform in Public Health Preparedness ATLANTA, GA - May 29, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, voiced strong support for the newly announced bipartisan initiative by U.S. Senators Joni Ernst (R-IA) and Lisa Blunt Rochester (D-DE) to onshore the manufacturing of critical pharmaceutical supplies. The Critical Infrastructure Manufacturing Feasibility Act seeks to reduce reliance on foreign sources for key medical products - directly aligning with GeoVax's mission to rebuild U.S.-based vaccine manufacturing and strengthen national preparedness. 'We are seeing a unified, national groundswell - from Congress, the White House, HHS, FDA, BARDA, and commissions like NSCEB - calling for the onshoring of America's vaccine manufacturing base,' said David Dodd, Chairman and CEO of GeoVax. 'GeoVax is purpose-built to answer that call, with a clinically validated MVA platform, a domestic manufacturing strategy, and a focus on pandemic responsiveness and protection of the immunocompromised.' Rebuilding U.S. Biomanufacturing Through Coordinated Federal Action The Senate initiative complements a cascade of government actions to bring the manufacturing of essential medical countermeasures - including vaccines - back to U.S. soil including: These actions reflect growing bipartisan recognition that national health security depends on resilient, scalable domestic vaccine capacity. MVA Technology: Protecting the Immunocompromised with Durable, Multi-Antigen Vaccines GeoVax's MVA platform supports a pipeline of multi-antigen vaccines, including GEO-CM04S1 (COVID-19), primarily targeted to address the current unmet needs inducing broad T-cell and antibody responses among immunocompromised individuals, overcoming the limitations of single-antigen vaccines. GeoVax's MVA vaccines align with FDA and HHS goals to advance diversified, multi-antigenic strategies that provide broader, longer-lasting protection across high-risk groups. Enabling U.S. Biomanufacturing Through Equip-A and BARDA RRPV: A Roadmap to Rapid, U.S.-Based Vaccine Production GeoVax's progressing advanced MVA manufacturing process is anticipated to eliminate the need for pathogen-free eggs and leverage a continuous avian cell line system, directly supporting the objectives of the federal government's EQUIP-A-Pharma initiative. This HHS-ASPR-DARPA program aims to create agile, point-of-care pharmaceutical production capabilities using modular, AI-driven platforms. Additionally, GeoVax's proposal - 'Innovation in Clinical Manufacturing of MVA-Vectored COVID-19 Vaccines' - was selected by BARDA's Rapid Response Partnership Vehicle (RRPV), pending funding availability. The program is designed to accelerate the scale-up of advanced U.S.-based MVA vaccine manufacturing. The proposal is designed to: If funded, this effort is expected to create a scalable, resilient domestic manufacturing platform essential for the rapid deployment of MVA-based vaccines like GEO-CM04S1 (COVID-19) and GEO-MVA (Mpox/smallpox). Platform Alignment with National Priorities GeoVax's MVA-based vaccines embody the shift in U.S. public health strategy away from single-antigen platforms and toward multi-antigen, durable, and safe alternatives. These vaccines are specifically engineered to meet the needs of high-risk populations - including the 40+ million immunocompromised Americans who may not respond effectively to mRNA and other vaccines that focus primarily on inducing antibody immunity. GeoVax's U.S.-controlled MVA platform addresses key government objectives: Call for Continued Bipartisan Momentum 'With renewed bipartisan focus on U.S. medical independence, there is no better time to invest in American-homegrown vaccine innovation,' added Dodd. 'We urge lawmakers and federal agencies to continue supporting domestic capacity, biodefense readiness, and equitable access to advanced medical countermeasures to protect both our national security and our most vulnerable populations.' About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: [email protected] 678-384-7220 Investor Relations Contact: [email protected] 212-698-8696
Yahoo
23-05-2025
- Business
- Yahoo
Bipartisan effort launched to onshore manufacturing of key supplies never before 'Made in USA'
EXCLUSIVE: Senators from both sides of the aisle will put forward a resolution calling on Commerce Secretary Howard Lutnick to seek out new sites and critical infrastructure for high-demand products that are currently not made in America, and analyze the viability of making such products here. Senate Small Business & Entrepreneurship Committee chairwoman Joni Ernst, R-Iowa, and Sen. Lisa Blunt Rochester, D-Del., came together Friday to launch the effort – citing the dual need for onshoring supply chains while bolstering the U.S. workforce. The Critical Infrastructure Manufacturing Feasibility Act would force Lutnick to report within 18 months on critical infrastructure sectors where products face material, sourcing, or supply-chain constraints that prevent them from being domestically produced. The Commerce Department would then have to analyze the feasibility of producing that product in the U.S. – and whether such products' newly-onshore production can be established in underserved rural areas and industrial parks. Lawmakers Take Action After Report Shows Biden-era Sba Failed To Probe 2 Million To Alleged Covid Aid Fraudsters Both Ernst's and Blunt Rochester's states are vastly rural. In the latter, suburban sprawl from Wilmington gives way to miles of coastal plain. Read On The Fox News App In recent years, the cities of Newark and Middletown have seen a boom in industrial parks and warehouses for major companies like Amazon seeking out the First State's famously low-tax and tax-free environs. "Supply chains are key to global competitiveness and our national security," Blunt Rochester told Fox News Digital. "This bipartisan legislation will help us identify where we rely too heavily on foreign imports for critical infrastructure and explore how we can bring that manufacturing home." House Small Business Committee Releases Report On Biden-era Electioneering The Delawarean added that strengthening domestic production not only protects our supply chains, "it supports American jobs, revitalizes local economies, and reinforces our nation's resilience if global manufacturing disruptions occur." Ernst added that the bill seeks to make the U.S. less dependent on foreign adversaries for critical infrastructure and key manufacturing supply chain preservation. "I am working to make 'Made in America' the norm instead of the exception," she said. "That starts with ensuring that our manufacturers are able to get the materials they need right here instead of having to import supplies from halfway around the world. Beyond boosting domestic industry, this bill is also about safeguarding our national security by ensuring that we are not dependent on any foreign adversary for critical goods that we need." Ernst has also spearheaded efforts to onshore the pharmaceutical supply chain from China. Many key ingredients in medicines are not produced in the U.S., and instead predominantly in Ireland and China. While one is a longtime U.S. ally, the other's involvement in the supply chain could lead to national security risks, critics have article source: Bipartisan effort launched to onshore manufacturing of key supplies never before 'Made in USA'
